Mithra Pharmaceuticals SA logo

MITRA - Mithra Pharmaceuticals SA Share Price

€20.6 0.1  0.2%

Last Trade - 4:35pm

Sector
Healthcare
Size
Mid Cap
Market Cap £762.7m
Enterprise Value £775.8m
Revenue £69.0m
Position in Universe 255th / 846
Bullish
Bearish
Unlock MITRA Revenue
Momentum
Relative Strength (%)
1m +7.41%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
154.5
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
19.0 20.4 22.5 32.0 57.9 96.5 35.5 79.2 +38.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, MithraPharmaceuticals SA revenues decreased 87% to EUR2.5M. Netloss applicable to common stockholders excludingextraordinary items decreased 64% to EUR34M. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Lower netloss reflects Fair Value Adjustments on Other Assetsdecrease of 94% to EUR5.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MITRA Revenue Unlock MITRA Revenue

Net Income

MITRA Net Income Unlock MITRA Revenue

Normalised EPS

MITRA Normalised EPS Unlock MITRA Revenue

PE Ratio Range

MITRA PE Ratio Range Unlock MITRA Revenue

Dividend Yield Range

MITRA Dividend Yield Range Unlock MITRA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MITRA EPS Forecasts Unlock MITRA Revenue
Profile Summary

Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 13, 1999
Public Since June 30, 2015
No. of Shareholders: n/a
No. of Employees: 172
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Euronext - Brussels
Shares in Issue 42,714,097
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MITRA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MITRA
Upcoming Events for MITRA
Frequently Asked Questions for Mithra Pharmaceuticals SA
What is the Mithra Pharmaceuticals SA share price?

As of 4:35pm, shares in Mithra Pharmaceuticals SA are trading at €20.6, giving the company a market capitalisation of £762.7m. This share price information is delayed by 15 minutes.

How has the Mithra Pharmaceuticals SA share price performed this year?

Shares in Mithra Pharmaceuticals SA are currently trading at €20.6 and the price has moved by -12.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mithra Pharmaceuticals SA price has moved by -16.14% over the past year.

What are the analyst and broker recommendations for Mithra Pharmaceuticals SA?

Of the analysts with advisory recommendations for Mithra Pharmaceuticals SA, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mithra Pharmaceuticals SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Mithra Pharmaceuticals SA next release its financial results?

Mithra Pharmaceuticals SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Mithra Pharmaceuticals SA dividend yield?

Mithra Pharmaceuticals SA does not currently pay a dividend.

Does Mithra Pharmaceuticals SA pay a dividend?

Mithra Pharmaceuticals SA does not currently pay a dividend.

When does Mithra Pharmaceuticals SA next pay dividends?

Mithra Pharmaceuticals SA does not currently pay a dividend.

How do I buy Mithra Pharmaceuticals SA shares?

To buy shares in Mithra Pharmaceuticals SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mithra Pharmaceuticals SA?

Shares in Mithra Pharmaceuticals SA are currently trading at €20.6, giving the company a market capitalisation of £762.7m.

Where are Mithra Pharmaceuticals SA shares listed? Where are Mithra Pharmaceuticals SA shares listed?

Here are the trading details for Mithra Pharmaceuticals SA:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: MITRA
What kind of share is Mithra Pharmaceuticals SA?

Based on an overall assessment of its quality, value and momentum, Mithra Pharmaceuticals SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mithra Pharmaceuticals SA share price forecast 2021?

Shares in Mithra Pharmaceuticals SA are currently priced at €20.6. At that level they are trading at 20.68% discount to the analyst consensus target price of 0.00.

Analysts covering Mithra Pharmaceuticals SA currently have a consensus Earnings Per Share (EPS) forecast of -0.563 for the next financial year.

How can I tell whether the Mithra Pharmaceuticals SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mithra Pharmaceuticals SA. Over the past six months, the relative strength of its shares against the market has been 7.54%. At the current price of €20.6, shares in Mithra Pharmaceuticals SA are trading at 7.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mithra Pharmaceuticals SA PE Ratio?

The Mithra Pharmaceuticals SA PE ratio based on its reported earnings over the past 12 months is 23.59. The shares are currently trading at €20.6.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Mithra Pharmaceuticals SA?

Mithra Pharmaceuticals SA's management team is headed by:

Guy Debruyne - NED
Gaetan Servais - NED
Marc Coucke - NEC
Christophe Marechal - CFO
Jean-Michel Foidart - EDR
Freya Loncin - NED
Jean-Manuel Fontaine - VPR
Benjamin Brands - OTH
Alexandra Deschner - DIR
Graham Dixon - CSO
M. Christian Moretti - NED
Renaat Baes - OTH
Leon Van Rompay - CEO
Who are the major shareholders of Mithra Pharmaceuticals SA?

Here are the top five shareholders of Mithra Pharmaceuticals SA based on the size of their shareholding:

Fornieri (Francois) Individual Investor
Percentage owned: 23.22% (9.92m shares)
Coucke (Marc) Individual Investor
Percentage owned: 15.04% (6.42m shares)
Meusinvest Venture Capital
Percentage owned: 11.63% (4.97m shares)
Versluys (Bart) Individual Investor
Percentage owned: 3.98% (1.70m shares)
OGEO Fund OFP Corporation
Percentage owned: 2.77% (1.18m shares)
Similar to MITRA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.